[
  {
    "ts": "2025-08-04T20:30:00+00:00",
    "headline": "Knight Therapeutics and Incyte Amend Supply and Distribution Agreement to Add Retifanlimab and Axatilimab in Latin America",
    "summary": "MONTREAL, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) (\"Knight\") a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has expanded its existing relationship and amended its agreement with Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte (NASDAQ:INCY), for the exclusive rights to distribute retifanlimab (sold as ZYNYZ® in the United States and Europe) and axatilimab (sold as NIKTIMVO™ in the United States) in Latin",
    "url": "https://finance.yahoo.com/news/knight-therapeutics-incyte-amend-supply-203000552.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "6112b544-7524-36a7-bd8b-76626d07ea5f",
      "content": {
        "id": "6112b544-7524-36a7-bd8b-76626d07ea5f",
        "contentType": "STORY",
        "title": "Knight Therapeutics and Incyte Amend Supply and Distribution Agreement to Add Retifanlimab and Axatilimab in Latin America",
        "description": "",
        "summary": "MONTREAL, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) (\"Knight\") a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has expanded its existing relationship and amended its agreement with Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte (NASDAQ:INCY), for the exclusive rights to distribute retifanlimab (sold as ZYNYZ® in the United States and Europe) and axatilimab (sold as NIKTIMVO™ in the United States) in Latin",
        "pubDate": "2025-08-04T20:30:00Z",
        "displayTime": "2025-08-04T20:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/6f19f960aa8749173a3ec6cb85899dea",
          "originalWidth": 982,
          "originalHeight": 257,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ssoKuPl1bS.IGmti1_Z9Yg--~B/aD0yNTc7dz05ODI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/6f19f960aa8749173a3ec6cb85899dea.cf.webp",
              "width": 982,
              "height": 257,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ANVSHUd_Hgv99ClTKZZAfA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/6f19f960aa8749173a3ec6cb85899dea.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/knight-therapeutics-incyte-amend-supply-203000552.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/knight-therapeutics-incyte-amend-supply-203000552.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KHTRF"
            },
            {
              "symbol": "GUD.TO"
            },
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]